JP6375091B2 - 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 - Google Patents

腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 Download PDF

Info

Publication number
JP6375091B2
JP6375091B2 JP2016509298A JP2016509298A JP6375091B2 JP 6375091 B2 JP6375091 B2 JP 6375091B2 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 6375091 B2 JP6375091 B2 JP 6375091B2
Authority
JP
Japan
Prior art keywords
general formula
tamoxifen
derivative
her2
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016509298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522179A5 (https=
JP2016522179A (ja
Inventor
ノイジル、ジリ
ストルサ、ヤン
ワーナー、ルーカス
Original Assignee
ノイジル、ジリ
スマート ブレイン エス．アール．オー．
スマート ブレイン エス．アール．オー．
バイオテクノロジスキー ユスタヴ エーヴィー シーアール、ヴィー．ヴィー．アイ．
バイオテクノロジスキー ユスタヴ エーヴィー シーアール、ヴィー．ヴィー．アイ．
ケイケイシージー エージー
ケイケイシージー エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6375091(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by ノイジル、ジリ, スマート ブレイン エス．アール．オー．, スマート ブレイン エス．アール．オー．, バイオテクノロジスキー ユスタヴ エーヴィー シーアール、ヴィー．ヴィー．アイ．, バイオテクノロジスキー ユスタヴ エーヴィー シーアール、ヴィー．ヴィー．アイ．, ケイケイシージー エージー, ケイケイシージー エージー filed Critical ノイジル、ジリ
Publication of JP2016522179A publication Critical patent/JP2016522179A/ja
Publication of JP2016522179A5 publication Critical patent/JP2016522179A5/ja
Application granted granted Critical
Publication of JP6375091B2 publication Critical patent/JP6375091B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
JP2016509298A 2013-04-24 2014-04-07 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 Expired - Fee Related JP6375091B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZPV2013-308 2013-04-24
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (3)

Publication Number Publication Date
JP2016522179A JP2016522179A (ja) 2016-07-28
JP2016522179A5 JP2016522179A5 (https=) 2017-04-06
JP6375091B2 true JP6375091B2 (ja) 2018-08-15

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509298A Expired - Fee Related JP6375091B2 (ja) 2013-04-24 2014-04-07 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体

Country Status (21)

Country Link
US (1) US9896466B2 (https=)
EP (1) EP2989110B1 (https=)
JP (1) JP6375091B2 (https=)
KR (1) KR101764991B1 (https=)
CN (1) CN105452265B (https=)
AU (1) AU2014256546B2 (https=)
CA (1) CA2909994C (https=)
CY (1) CY1120821T1 (https=)
DK (1) DK2989110T3 (https=)
EA (1) EA029881B1 (https=)
ES (1) ES2699099T3 (https=)
GE (2) GEAP201813996A (https=)
HR (1) HRP20181872T1 (https=)
HU (1) HUE042239T2 (https=)
MD (1) MD4626C1 (https=)
NZ (1) NZ713589A (https=)
PL (1) PL2989110T3 (https=)
PT (1) PT2989110T (https=)
SI (1) SI2989110T1 (https=)
UA (1) UA116469C2 (https=)
WO (1) WO2014173374A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016290425A1 (en) * 2015-07-03 2018-01-18 Bayer Cropscience Aktiengesellschaft N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives with herbicidal action
US10556874B2 (en) * 2015-07-03 2020-02-11 Bayer Cropscience Aktiengesellschaft N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
RU2020116649A (ru) 2017-10-24 2021-11-30 Лунелла Байотек, Инк. Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания
US10980821B2 (en) 2017-11-24 2021-04-20 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
US11497759B2 (en) 2017-12-01 2022-11-15 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
EP3728300A4 (en) 2017-12-20 2021-08-11 Lunella Biotech, Inc. TARGETING OF MITOCHONDRIAL FISSION BY MDIVI-1 DERIVATIVES
CA3136811A1 (en) * 2019-04-16 2020-10-22 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504522A (ja) * 1990-10-01 1994-05-26 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 高親和性タモキシフェン誘導体とその使用
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
NZ602579A (en) * 2008-03-14 2013-12-20 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
CA2756820A1 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
CN105452265A (zh) 2016-03-30
EP2989110B1 (en) 2018-08-08
HUE042239T2 (hu) 2019-06-28
WO2014173374A1 (en) 2014-10-30
CN105452265B (zh) 2017-05-10
MD4626C1 (ro) 2019-11-30
EA201591918A1 (ru) 2016-02-29
JP2016522179A (ja) 2016-07-28
CA2909994A1 (en) 2014-10-30
HK1216317A1 (zh) 2016-11-04
CA2909994C (en) 2018-06-26
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
MD4626B1 (ro) 2019-04-30
US20160075726A1 (en) 2016-03-17
AU2014256546A1 (en) 2015-11-12
SI2989110T1 (sl) 2019-01-31
KR101764991B1 (ko) 2017-08-10
PT2989110T (pt) 2018-11-15
KR20150144756A (ko) 2015-12-28
US9896466B2 (en) 2018-02-20
NZ713589A (en) 2017-12-22
MD20150117A2 (ro) 2016-08-31
PL2989110T3 (pl) 2019-03-29
UA116469C2 (uk) 2018-03-26
DK2989110T3 (en) 2018-12-03
CY1120821T1 (el) 2019-12-11
AU2014256546B2 (en) 2017-03-30
EP2989110A1 (en) 2016-03-02
GEAP201813996A (en) 2018-03-12
ES2699099T3 (es) 2019-02-07
GEP20186868B (en) 2018-06-25

Similar Documents

Publication Publication Date Title
JP6375091B2 (ja) 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体
Burmaoglu et al. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents
Cervelli et al. Polyamines metabolism and breast cancer: state of the art and perspectives
JP2016522179A5 (https=)
Xu et al. NSAID–Au (I) complexes induce ROS-driven DAMPs and interpose inflammation to stimulate the immune response against ovarian cancer
Štarha et al. Platinum (II) iodido complexes of 7-azaindoles with significant antiproliferative effects: an old story revisited with unexpected outcomes
Wang et al. Novel mono-, bi-, tri-and tetra-nuclear copper complexes that inhibit tumor growth through apoptosis and anti-angiogenesis
Shan et al. First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway
Traversi et al. A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin
Alqahtani et al. Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
CN104592091B (zh) 一种含吲哚乙酸核心结构的化合物及其应用
CA3045365C (en) Compounds for treatment of senescence-related disorders
Senthilkumar et al. Synthesis and Evaluation of Anisomelic acid-like Compounds for the Treatment of HPV-Mediated Carcinomas
CZ304553B6 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ201466A3 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
WO2018017589A1 (en) Compounds for targeting cancer stem cells
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
Liu et al. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-N-arylacetamides as novel HSP90 C-terminal inhibitors
Adegbulugbe Synthesis and Evaluation of Tetramethoxy Stilbenes Related to Combretastatin A-4 as Potential Anticancer Agents
Fadilah Activity study of Kaempferia pandurata Roxb. extract as antiestrogen receptor (-) breast cancer cell line 3, 4-methylenedioxyamphetamine-MB-231 by molecular docking and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay
CN106928207A (zh) 肿瘤微管蛋白HIF‑1α双靶点抑制剂及其制备方法
CN121517467A (zh) 一种环金属化Ir(III)-AZT化合物及其制备方法与应用
Generation et al. Molecular Sciences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180721

R150 Certificate of patent or registration of utility model

Ref document number: 6375091

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees